NASD · Healthcare · Medical Devices · USA
Sight Sciences Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.
Sight Sciences develops interventional ophthalmology technologies for treating glaucoma and dry eye disease. The company offers OMNI and SION surgical systems for glaucoma procedures performed in combination with cataract surgery or as standalone treatments, and the TearCare system for dry eye disease management. Products are primarily sold in the United States through dedicated sales teams to eyecare providers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Sight Sciences Inc stock.
Overvalued: intrinsic value $3.13 per share, market price $10.49, margin of safety -234.7% (as of 2026-11-17).
A 1.4x revenue multiple, discounted for its losses, values the shares at $3.13; the price of $10.49 is 235% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
44 more in this industry show a wider margin of safety.
SGHT is overvalued (as of the 2026-11-17 close). A 1.4x revenue multiple, discounted for its losses, values the shares at $3.13; the price of $10.49 is 235% above that value.
$3.13 per share (as of the 2026-11-17 close), against a market price of $10.49. That is a margin of safety of -234.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.